Phase 2 trial will evaluate new investigational “pan-TB” regimen that includes three new compounds, in pursuit of a shorter, simpler TB treatment.
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) Collaboration announced plans to launch a Phase 2 clinical trial evaluating a novel four-drug regimen designed to shorten treatment for drug-sensitive TB from six months to four. Enrollment is expected to begin in the third quarter of 2027 at trial sites across Africa and Asia.
The trial will include two new investigational compounds, TBD09 and TBD11, initially advanced through the TB Drug Accelerator and now being developed by the Gates Medical Research Institute. The regimen also includes two compounds from TB Alliance: sorfequiline, an investigational compound currently in Phase 2 for the treatment of drug-sensitive TB and pretomanid, which is recommended by the World Health Organization to treat rifampicin-resistant/multidrug-resistant TB as part of the bedaquiline, pretomanid and linezolid (BPaL) regimen, except in certain circumstances. Together, the four compounds combine different mechanisms of action which could potentially shorten the treatment course.
Source : TB Alliance
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.